Recombinant VWF anticorps (AA 1815-1939)
-
- Antigène Voir toutes VWF Anticorps
- VWF (Von Willebrand Factor (VWF))
- Type d'anticorp
- Recombinant Antibody
-
Épitope
- AA 1815-1939
-
Reactivité
- Humain
-
Hôte
- Lapin
-
Clonalité
- Monoclonal
-
Conjugué
- Cet anticorp VWF est non-conjugé
-
Application
- Western Blotting (WB), Immunoprecipitation (IP), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Purification
- Purified
- Pureté
- Protein A affinity chromatography
- Immunogène
- Amino acids 1815-1939 from the human protein were used as the immunogen for this recombinant vWF antibody.
- Clone
- VWF-1859R
- Isotype
- IgG kappa
- Top Product
- Discover our top product VWF Anticorps primaire
-
-
- Indications d'application
-
The optimal dilution of the recombinant vWF antibody for each application should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. Western blot: 1-2 μg/mL,Immunoprecipitation: 1-2 μg/500 μg lysate,Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 1-2 μg/mL for 30 minutes at RT
- Restrictions
- For Research Use only
-
- Concentration
- 1 mg/mL
- Buffer
- 1 mg/mL in 1X PBS, BSA free, sodium azide free
- Agent conservateur
- Azide free
- Stock
- 4 °C,-20 °C
- Stockage commentaire
- Store the recombinant vWF antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
-
- Antigène
- VWF (Von Willebrand Factor (VWF))
- Autre désignation
- von Willebrand Factor / vWF (VWF Produits)
- Synonymes
- anticorps VWF, anticorps si:ch1073-474e24.1, anticorps F8VWF, anticorps VWD, anticorps 6820430P06Rik, anticorps AI551257, anticorps B130011O06Rik, anticorps C630030D09, anticorps von Willebrand factor, anticorps Von Willebrand factor, anticorps VWF, anticorps vwf, anticorps Vwf
- Sujet
- Von Willebrand Factor (vWF) is a multimeric glycoprotein that is found in endothelial cells, plasma and platelets. It acts as a carrier protein for Factor VIII and promotes platelet adhesion and aggregation. vWF undergoes a variety of posttranslational modifications that influence the affinity and availability for Factor VIII, including cleavage of the propeptide and formation of N-terminal disulfide bonds. This antibody helps to establish the endothelial nature of some lesions of disputed histogenesis, e.g. Kaposi's sarcoma and cardiac myxoma. It is widely used for differentiating vascular lesions from those of other tissue differentiation within a panel of other vascular markers although not all tumors of endothelial differentiation contain this antigen.
-